March 22, 2016
Vancouver, BC – Dr. Alan Winter, President and CEO of Genome British Columbia is pleased to announce the appointment of Mr. Lenard Boggio and Dr. Paul Terry to its Board of Directors.
Len Boggio retired from his role as audit partner with PricewaterhouseCoopers in 2012. During his thirty years at the firm, he provided services primarily to publicly listed companies, including those in the technology, mining and financial services industry sectors and in the final years of his career was the leader of the firm’s British Columbia mining industry practice.
He graduated from the University of Windsor, Ontario with both a BA in Economics and Politics and a BComm in Accounting, earning a place on the President’s Role of Scholars. He achieved a silver medal in BC and placed fifth in Canada in the Chartered Accountants uniform final examinations and is a Fellow Chartered Professional Accountant (FCPA, FCA) and a US Certified Public Accountant (CPA – Illinois).
Mr. Boggio has completed the national program of the Institute of Corporate Directors of Canada and earned his ICD.D designation. He serves as an independent director on the boards of several publicly listed companies, and is a Commissioner of the Financial Institutions Commission of BC. He is a past president of the Institute of Chartered Accountants of BC (now the Chartered Professional Accountants of BC) and the Chair of the Canadian Institute of Chartered Accountants for the years from 2014 to 2016.
Paul Terry is the President and CEO of PHEMI, a big data warehouse company. He is also an adjunct professor at Simon Fraser University and a partner with Magellan Angel Partners.
For over a decade Dr. Terry served as the secretary/treasurer and technology adviser for the Michael Smith Foundation for Health Research and was one of the Entrepreneurs-in-Residence at SFU Venture Labs. Prior to this he was the CTO and cofounder of both OctigaBay Systems (acquired by Cray Inc.) and Abatis Systems (acquired by Redback Networks in one of the largest technology acquisitions in Canadian history).
Currently he serves on the Board of Directors for Providence Health Care, advising on its subcommittees for innovation, quality, EMR, and next-generation data strategies in healthcare. Dr. Terry also serves on the Board of Directors for Life Sciences BC and Molecular You, and is an advisor to the BC provincial government on next-generation data strategies. He is a member of the BC Institute for Health Innovation.
Dr. Terry holds an MBA from the Cranfield School of Management, a marketing diploma from the Chartered Institute of Marketing, a PhD in Electrical Engineering and an honours Bachelor’s degree from the University of Liverpool. In 2000, he was included in Canada’s “Top 40 Under 40″.
“The appointment of Lenard and Paul adds a unique set of expertise to our Board that will better support Genome BC’s efforts to increase the impact of genomics on our economy and support entrepreneurship and commercialization,” says Dr. Winter. “We look forward to working with each of these exceptional individuals.”
More info at: www.genomebc.ca/about/people/board-of-directors.
